1►先声抗失眠新药获批上市6月20日,先声药业发布公告称,创新型抗失眠药盐酸达利雷生片(商品名:科唯可®)已于2025年6月17日获NMPA批准上市,用于治疗以入睡困难和/或睡眠维持困难为特征的成人失眠患者,且未被作为精神药品管制。截图来源:NMPA官网达利雷生在华获批主要基于一项随机、双盲、安慰剂平行对照的中国多中心注册性Ⅲ期临床试验以及Idorsia的全球临床试验中的有效性与安全性数据。中国的...
Source Link1►先声抗失眠新药获批上市6月20日,先声药业发布公告称,创新型抗失眠药盐酸达利雷生片(商品名:科唯可®)已于2025年6月17日获NMPA批准上市,用于治疗以入睡困难和/或睡眠维持困难为特征的成人失眠患者,且未被作为精神药品管制。截图来源:NMPA官网达利雷生在华获批主要基于一项随机、双盲、安慰剂平行对照的中国多中心注册性Ⅲ期临床试验以及Idorsia的全球临床试验中的有效性与安全性数据。中国的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.